地诺单抗治疗侵袭性成骨细胞瘤伴继发性动脉瘤性骨囊肿。

IF 0.9 Q4 ONCOLOGY
Rare Tumors Pub Date : 2021-08-29 eCollection Date: 2021-01-01 DOI:10.1177/20363613211034710
Karlton Wong, Jomjit Chantharasamee, Scott Nelson, Mark A Eckardt, Kambiz Motamedi, Francis J Hornicek, Arun S Singh
{"title":"地诺单抗治疗侵袭性成骨细胞瘤伴继发性动脉瘤性骨囊肿。","authors":"Karlton Wong,&nbsp;Jomjit Chantharasamee,&nbsp;Scott Nelson,&nbsp;Mark A Eckardt,&nbsp;Kambiz Motamedi,&nbsp;Francis J Hornicek,&nbsp;Arun S Singh","doi":"10.1177/20363613211034710","DOIUrl":null,"url":null,"abstract":"<p><p>Osteoblastomas and aneurysmal bone cysts (ABC) are rare benign bone tumors that make up about 1%-2% of primary bone malignancies, typically occurring in young patients with a median age of 20 years, most commonly effecting the axial skeleton. ABCs may develop independently as primary lesions, or secondary to other bony lesions including osteoblastomas, chondroblastomas, and giant cell tumors. Treatment of unresectable or extensive osteoblastomas can be challenging. In 2013, the Food and Drug Administration (FDA) approved denosumab for the treatment of giant cell tumors of the bone due to its efficacy in these morbid bony lesions. Various case reports have shown that osteoblastomas can respond to denosumab. Furthermore, numerous ABC case reports have described the efficacy of denosumab in these situations. We herein describe a unique case of a young patient with an aggressive osteoblastoma and secondary ABCs who was successfully treated with denosumab.</p>","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2021-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2c/5f/10.1177_20363613211034710.PMC8408893.pdf","citationCount":"5","resultStr":"{\"title\":\"Aggressive osteoblastoma with a secondary aneurysmal bone cyst treated with denosumab.\",\"authors\":\"Karlton Wong,&nbsp;Jomjit Chantharasamee,&nbsp;Scott Nelson,&nbsp;Mark A Eckardt,&nbsp;Kambiz Motamedi,&nbsp;Francis J Hornicek,&nbsp;Arun S Singh\",\"doi\":\"10.1177/20363613211034710\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Osteoblastomas and aneurysmal bone cysts (ABC) are rare benign bone tumors that make up about 1%-2% of primary bone malignancies, typically occurring in young patients with a median age of 20 years, most commonly effecting the axial skeleton. ABCs may develop independently as primary lesions, or secondary to other bony lesions including osteoblastomas, chondroblastomas, and giant cell tumors. Treatment of unresectable or extensive osteoblastomas can be challenging. In 2013, the Food and Drug Administration (FDA) approved denosumab for the treatment of giant cell tumors of the bone due to its efficacy in these morbid bony lesions. Various case reports have shown that osteoblastomas can respond to denosumab. Furthermore, numerous ABC case reports have described the efficacy of denosumab in these situations. We herein describe a unique case of a young patient with an aggressive osteoblastoma and secondary ABCs who was successfully treated with denosumab.</p>\",\"PeriodicalId\":46078,\"journal\":{\"name\":\"Rare Tumors\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2021-08-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2c/5f/10.1177_20363613211034710.PMC8408893.pdf\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Rare Tumors\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/20363613211034710\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rare Tumors","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20363613211034710","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 5

摘要

成骨细胞瘤和动脉瘤性骨囊肿(ABC)是罕见的良性骨肿瘤,约占原发性骨恶性肿瘤的1%-2%,通常发生在中位年龄为20岁的年轻患者中,最常见于中轴骨骼。abc可以独立发展为原发性病变,也可以继发于其他骨病变,包括成骨细胞瘤、成软骨细胞瘤和巨细胞瘤。不可切除或广泛的成骨细胞瘤的治疗是具有挑战性的。2013年,美国食品和药物管理局(FDA)批准了denosumab用于治疗骨巨细胞瘤,因为它对这些病态的骨病变有疗效。各种病例报告显示成骨细胞瘤对地诺单抗有反应。此外,许多ABC病例报告描述了denosumab在这些情况下的疗效。我们在此描述一个独特的情况下,一个年轻的患者与侵袭性成骨细胞瘤和继发性abc谁是成功地用地诺单抗治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Aggressive osteoblastoma with a secondary aneurysmal bone cyst treated with denosumab.

Aggressive osteoblastoma with a secondary aneurysmal bone cyst treated with denosumab.

Aggressive osteoblastoma with a secondary aneurysmal bone cyst treated with denosumab.

Aggressive osteoblastoma with a secondary aneurysmal bone cyst treated with denosumab.

Osteoblastomas and aneurysmal bone cysts (ABC) are rare benign bone tumors that make up about 1%-2% of primary bone malignancies, typically occurring in young patients with a median age of 20 years, most commonly effecting the axial skeleton. ABCs may develop independently as primary lesions, or secondary to other bony lesions including osteoblastomas, chondroblastomas, and giant cell tumors. Treatment of unresectable or extensive osteoblastomas can be challenging. In 2013, the Food and Drug Administration (FDA) approved denosumab for the treatment of giant cell tumors of the bone due to its efficacy in these morbid bony lesions. Various case reports have shown that osteoblastomas can respond to denosumab. Furthermore, numerous ABC case reports have described the efficacy of denosumab in these situations. We herein describe a unique case of a young patient with an aggressive osteoblastoma and secondary ABCs who was successfully treated with denosumab.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Rare Tumors
Rare Tumors ONCOLOGY-
CiteScore
1.50
自引率
0.00%
发文量
15
审稿时长
15 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信